Kornimate/medical-research-clean huggingface dataset:
combination of oral supplement with fatty acids, vitamin b6, perilla, and liquorice with nasal steroids for the treatment of allergic rhinitis

Conditions: Allergic Rhinitis

Summary: previous studies on the association between the development of allergic diseases and diet indicate the involvement of dietary fatty acids (fa) in the acceleration and/or inhibition of allergic diseases. edible oils contain various fas, but their composition depends on the materials from which they are extracted. fas are characterised by the presence or absence of a carbon double bond in their structure; saturated fas (palmitic acid, stearic acid, etc.) have no carbon double bond, while unsaturated fas contain at least one carbon double bond. among the unsaturated fas, omega-3 fas (such as alpha-linolenic acid \[ala\], eicosapentaenoic acid \[epa\] and docosahexaenoic acid \[dha\]) and omega-6 fas (such as linoleic acid \[la\] and arachidonic acid \[ara\]) are classified as essential fas. various types of bioactivity of dietary essential fas have been reported in health and disease studies, including immunity, allergy and inflammation. human studies, for example, have shown an association between the quality of dietary fas and the incidence of allergic diseases. translated with deepl.com (free version)


Eligibility criteria:
inclusion criteria: * age between 18 and 80 years; * confirmed diagnosis of ar already treated with scarce or absent results by general practitioners exclusion criteria: * pregnancy or breastfeeding; * concomitant asthma without stable control; * chronic obstructive and restrictive lung disease; * autoimmune and collagen diseases; * acute sinusitis, nasal or upper respiratory tract infections in acute phase; * cardiovascular, hepatic, or renal disease; * other poorly controlled serious or chronic diseases; * taking medications that may affect the immune response; * previous nasal surgery; * immunotherapy in the 3 years prior to enrolment, or the ones who planned to receive immunotherapy; * patients who did not sign the informed consent for;

Keywords: allergic rhinitis intranasal corticosteroids rhinosinusitis fatty acid
the effect of uv-irradiation on cutaneous cicatrices

Conditions: Skin Cicatrices

Summary: the purpose of this study is to examine the effect of uv-irradiation on human cutaneous cicatrices by clinical examinations and histological, immunohistochemical and biochemical analyses.


Eligibility criteria:
inclusion criteria: * non-smoking volunteers, * skintypes ii or iii exclusion criteria: * atopic dermatitis, * tendency to produce keloids or hypertrophic scars, * exposure of uv light during the last 3 months, * medical treatment
lidocaine infusion for pain after herniotomy

Conditions: Hernia, Inguinal; Lidocaine; Pain, Postoperative; Chronic Pain

Summary: this study seeks to investigate lidocaine infusion to reduce occurrence of chronic postoperative pain at 3-month after inguinal herniotomy

inguinal hernia repair is associated with a 5%-30% incidence of chronic pain; however, the pathogenesis remains unknown, and few studies have assessed chronic pain as the primary aim of the study. lidocaine infusion could be a possible approach to reducing the prevalence of chronic pain after herniotomy. recently, a meta-analysis concluded a modest but statistically significant reduction of pain severity in the first four postoperative hours measured by the visual analogue scale (mean difference, -0.84; 95% ci, -1.10 to -0.59). however, a more recent meta-analysis found that only limited clinical data and biological plausibility support lidocaine infusions for the prevention of postoperative persistent pain (odds ratio, 0.29; 95% ci, 0.18 to 0.48). this study was designed to investigate whether lidocaine infusion after inguinal herniotomy would lower the incidence of chronic postoperative pain.

Eligibility criteria:
inclusion criteria: * patients scheduled to undergo unilateral inguino herniotomy exclusion criteria: * (1)asa classification status iii or above * (2)body weight\<35kg * (3)liver cirrhosis * (4)a history of previous herniotomy * (5)pregnancy * (6)severe arrhythmia * (7)congestive heart failure * (8)opioid or steroid use 6 months before surgery * (9)allergy to lidocaine * (10)chronic pain syndrome (any type) * (11)emergency surgery * (12)incapacity to give an informed consent, visual dysfunction or severe mental disorders

Keywords: chronic postoperative pain lidocaine infusion inguinal herniotomy
oral rehydration therapy in children with mild to moderate dehydration

Conditions: Parent; Attitudes

Summary: the purpose of this study is to determine parental attitudes towards oral rehydration therapy for children with mild to moderate dehydration.


Eligibility criteria:
inclusion criteria: * parents of dehydrated children aged 0-18 exclusion criteria: * child with severe dehydration * child with chronic disease causing dehydration

Keywords: dehydration
severe necrotizing enterocolitis in preterm newborns <1500g using probiotics

Conditions: Infectious Diseases

Summary: the purpose of this study is to know the effects of probiotics on the incidence of necrotizing enterocolitis (nec) in preterm infants less than 1500 g.

the investigators performed a clinical, randomized, double-blind trial in preterm infants \<1500g from march 1, 2010 to february 28, 2012. group a received enteral stimulation trophic five days and later increments 20ml/k/day of breast milk or formula for premature; the group b apart from the above the probiotic lactobacillus acidophilus (boucardii strain) 1 x109 colonic forming unit (cfu)/ day for 4 weeks was added. gastric tolerance, evolution, reason for discharge, and the development of necrotizing enterocolitis was monitored. the diagnosis of necrotizing enterocolitis was made by the treating physician according to bell's criteria and was blinded to group assignments.the formulas were prepared by one of the investigators according to the group each patient was assigned. using sterile technique, the probiotic with 1x109 (cfu) lactobacillus acidophilus (boucardii strain) was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks to fresh supplement breast milk or formula for preterm infants. in case of control group only breast milk or formula for preterm infants was used. all formulas were labeled for each patient and were delivered to the nurse in charge of infant feeding at 9:00 and 21:00 h. characteristics of sample size and statistical analysis: sample size showed that the investigators needed 190 total preterm infants, based on the expected 50% decrease in the incidence of severe necrotizing enterocolitis in preterm neonates who received probiotics compared with control group with α 0.05 and β 0.20. student´s t test or mann whitney u test were performed for mean differences regarding the general characteristics in the two study groups, chi square or fisher´s test for differences in proportions for mortality and complications between groups.

Eligibility criteria:
inclusion criteria: * we studied 150 preterm newborns \<1500gr who were recruited on the day that began enteral feeding according to the decision of the treating physician. exclusion criteria: * preterm infants \> 1500g with apgar score \<6 at 5 minutes, gastrointestinal malformations, fetopathies, patent ductus arteriosis with hemodynamic decompensation, asphyxia, and nec suspected as classified by bell were excluded from the study.

Keywords: necrotizing enterocolitis probiotics preterm newborns
the beneficial role of percutaneous coronary intervention over optimal medical therapy in elderly patients with coronary artery disease

Conditions: Coronary Artery Disease

Summary: the primary purpose of this study is to determine whether pci added to omt could be superior over omt alone in the prevention of late adverse cardiac and cerebro-vascular events in elderly patients with coronary artery disease (cad) during the additional 12 months.

study design * prospective, randomized, multi-center study of each 1600 subjects enrolled. * eligible subjects will be randomized 1:1 to a) pci added to omt (n=800) vs. b) omt alone(n=800). subsequently, subjects in pci added to omt group will be randomly assigned to everolimus eluting stent(n=400) vs. zotarolimus eluting sten(n=400). all subjects will be followed for 1 year after randomization. additional long-term follow-up (2- or 3-year) will be preceded in the next plan after 1-year study period. * subjects with cad who meet all inclusion and exclusion criteria will be included * clinical and laboratory follow-up should be performed.

Eligibility criteria:
inclusion criteria: 1. patients with cad and those in whom initial ccs class i to iii angina or braunwald classification less than iib 2. patients with age 75 years or older 3. patients receiving omt (one or two anti-platelet agents, beta-blockers, calcium channel blockers, nitrates, angiotensin converting enzyme inhibitors (aceis) or angiotensin receptor blockers (arbs), and statin) 4. patients with stenosis of at least 70% in at least one proximal epicardial coronary artery or objective evidence of myocardial ischemia (substantial changes in st-segment depression or t-wave inversion on the resting electrocardiogram or inducible ischemia with either exercise or pharmacologic vasodilator stress) 5. patients with signed informed consent exclusion criteria: 1. patients with persistence of ccs iv angina 2. resting chest pain (≥ braunwald classification iib) 3. patients who experienced a markedly positive stress test (substantial st- segment depression or hypotensive response during stage 1 of the bruce protocol) 4. patients with age 85 years or older 5. patients with refractory chf or cardiogenic shock 6. patients with an ef of less than 30% 7. patients who have received revascularization within the previous 6 months 8. patients with coronary anatomy not suitable for pci 9. life expectancy ≤ 2 year

Keywords: coronary artery disease 75years of age or older
exploring the immune response to sars-cov-2 covid-19 vaccines in patients with relapsing multiple sclerosis (rms) treated with ofatumumab

Conditions: Relapsing Multiple Sclerosis

Summary: this study aimed to understand whether patients with relapsing multiple sclerosis (rms) can mount an immune response to sars-cov-2 mrna vaccines (initial vaccinations or booster vaccines) when vaccinated either before initiation of ofatumumab treatment or at least 4 weeks after commencing ofatumumab treatment.

this was a four cohort, multicenter, open-label, prospective study of 34 (optionally up to 60) patients who had relapsing multiple sclerosis (rms) planning to undergo a sars-cov-2 mrna vaccination (initial vaccinations or booster vaccines) as part of clinical routine. the maximal duration of the study for an individual patient was 22 months. * the first cohort was rms patients receiving sars-cov-2 mrna vaccine (initial vaccinations or booster vaccines) as part of clinical routine prior to starting ofatumumab treatment. * the second cohort was participants receiving sars-cov-2 mrna vaccine (initial vaccinations or booster vaccines) as part of clinical routine while already stable on ofatumumab treatment for at least 4 weeks (since first dose). cohort 1a - patients received first sars-cov-2 vaccination within the study prior to starting ofatumumab treatment. cohort 1b - patients had already completed initial vaccination cycle and received a booster vaccine within the study prior to starting ofatumumab treatment. cohort 2a - patients who received their first sars-cov-2 vaccination within the study while already stable on ofatumumab treatment for at least 4 weeks (since the first dose). cohort 2b - patients who had already completed their initial vaccination cycle and received a booster vaccine within the study while already stable on ofatumumab treatment for at least 4 weeks (since the first dose). development of sars-cov-2 specific t-cells and functional anti-sars-cov-2 antibodies were investigated for up to 18 months after the participants' vaccination.

Eligibility criteria:
inclusion criteria: * relapsing multiple sclerosis (rms) diagnosis * eligible for ofatumumab treatment * willing and eligible to receive sars-cov-2 mrna vaccine exclusion criteria: * known prior or current covid-19 infection * previous treatment with btk inhibitor or anti-cd20 therapy other than ofatumumab * no previous vaccination with a non-modrna sars-cov-2 vaccine. other protocol-defined inclusion/exclusion criteria may apply

Keywords: covid-19 sars-cov-2 mrna vaccine immune response ofatumumab relapsing multiple sclerosis rms adult ms
premature luteinization prevention by gnrh antagonist in patients undergoing iui

Conditions: Infertility

Summary: premature luteinization in patients undergoing iui can occur in up to 24% of cycles. these patients, according to recent data, have a lower pregnancy rate than controls. the possibility to avoid premature luteinization with gnrh antagonist may restore the chances of achieving a pregnancy in these women.

the purpose of this study was to investigate whether a subset of patients benefits from gnrha administration during iui. pl was tested for in patients who were undergoing artificial insemination procedures, and the effect of gnrha on pr in patients who

Eligibility criteria:
inclusion criteria: * previous failed iui cycle with premature luteinization exclusion criteria: * 39 years or older * not eligible for iui (patent tubes, \> 3 million capacitated spermatozoa) * 4 previous iui cycles

Keywords: gnrh antagonist iui
spurring innovation to promote hiv testing: an rct evaluating crowdsourcing

Conditions: HIV

Summary: crowdsourcing may be a powerful tool to spur the development of innovative videos to promote hiv testing among key populations such as men who have sex with men (msm) and transgender (tg) individuals. the purpose of this randomized controlled trial is to compare the effect of a crowdsourced video and a conventional video on first-time hiv testing among msm and tg in china. the crowdsourced video was developed using an open contest, formal transparent judging, and an incentive of marketing promotion. the hypothesis is that a crowdsourced video will be equivalent (within a margin of 3%) to a conventional video in terms of self-reported first-time hiv testing within 3-4 weeks of watching the video.


Eligibility criteria:
inclusion criteria: * born biologically male or identify as transgender * 16 years or older * lifetime anal sex with another man * providing informed consent and active mobile phone number exclusion criteria: * hiv-infected * hiv-tested ever in the past

Keywords: contest crowdsourcing innovation randomized controlled trial china social entrepreneurship
tirbanibulin 1% ointment for the treatment of chronically sun-damaged skin on the face

Conditions: Actinic Keratosis

Summary: interventional, monocentric, national, single-arm, uncontrolled, open, prospective phase iv study. since this study is not powered for confirmative testing, analysis is done by descriptive statistics eligible ak patients receive tirbanibulin on sun-damaged areas of the face for five days, according to the smpc. diagnosis and monitoring of treatment effects are supported by uv imaging using canfield visia®. safety and efficacy are assessed at end of treatment visit (eot, approximately 3 days after the last dose, i.e, day 8 ± 2) and at a follow-up visit (fuv) 57 ± 7 d after the start of the treatment. uv images (canfield visia®) will be taken at baseline, eot and fuv, accompanied by conventional dermatological assessment according to clinical routine.


Eligibility criteria:
inclusion criteria: * informed consent * diagnosed with sun-damaged skin on the face and ak in the treatment area * willing and able to comply with all study procedures * use of medically acceptable contraception in males or females of child-bearing potential * 51 -100 years of age * negative pregnancy test at baseline in females of childbearing potential exclusion criteria: * allergy or intolerance towards the active ingredient or any of the constituents of the imp * any contraindication for the imp, according to the most recent version of the smpc * open lesions of any kind on the face * concomitant cutaneous malignancy in treatment area, including but not restricted to squamous skin cancer * immune deficiency * participation in another clinical trial during the last six months * pregnancy or lactation
a study of the pharmacokinetics of albiglutide in normal and renally impaired subjects.

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to assess the pharmacokinetics and safety of a single subcutaneously injected dose of albiglutide in subjects with type 2 diabetes mellitus with varying degrees of renal function, including subjects requiring hemodialysis.

this adaptive design, non-randomized, open-label, staggered parallel group study evaluates the pharmacokinetics and safety of a single subcutaneously injected dose of albiglutide in subjects with type 2 diabetes mellitus with varying degrees of renal function. during stage 1, a single dose of albiglutide will be administered to subjects with normal renal function and subjects with moderate-to-severe renal impairment not requiring hemodialysis. in addition to subjects with normal renal function and moderate renal impairment, stage 2 of the study will also include cohorts of subjects requiring hemodialysis, subjects with severe renal impairment not requiring hemodialysis, and potentially subjects with mild renal impairment.

Eligibility criteria:
inclusion criteria: * normal renal function or renal impairment * stable hemodialysis treatment for at least 3 months before screening and able to tolerate a hemodialysis treatment lasting 3-4 hours with blood flow rates of \>200ml/min (cohort 3 only) * neither pregnant nor lactating * hba1c 6-10.5% inclusive * females of childbearing potential must be practicing adequate contraception. exclusion criteria: * inability to meet the pk objectives of the study * history of hypoglycemia unawareness or severe hypoglycemia * liver function tests greater than or equal to 2 times the uln * clinically significant cardiovascular and/or cerebrovascular disease * positive test results for hepatitis b, hepatitis c, or hiv * documented hypertension or hypotension at screening * known hepatic or biliary abnormalities * current use of sulfonylureas * active history of tobacco use within 6 months before screening * donation of blood in excess of 500ml within 56 days before albiglutide dosing * receipt of any investigational drug within the 30days or 5 half lives, whichever is longer, before dosing * previous or current receipt of exenatide or any other glp-1 agonist

Keywords: albiglutide hemodialysis pharmacokinetics renal
a mindfulness meditation-based intervention for younger breast cancer survivors

Conditions: Younger Breast Cancer Survivors

Summary: younger women with breast cancer experience substantially greater distress and depressive symptoms than older women. these symptoms can hamper recovery and healthy behaviors that can reduce the risk of recurrence and/or other chronic diseases. the primary objective of this study is to evaluate the feasibility and preliminary efficacy of a mindfulness meditation-based intervention for this at-risk group of women. the investigators hypothesize that a structured program of mindfulness meditation will lead to significant improvements in psychological well-being (i.e., depression, stress), with corresponding improvements in health behaviors and biomarkers of cancer risk, in women diagnosed with breast cancer, prior to age 50. the investigators will also examine mechanisms for intervention effects, including increased mindfulness and ability to relax.


Eligibility criteria:
inclusion criteria: * women diagnosed with early, resectable breast cancer (stage 0, i, ii, or iii) prior to age 50 * have completed treatment with surgery, radiation, and/or chemotherapy at least 3 months previously. exclusion criteria: * have a breast cancer recurrence, metastasis, or another cancer diagnosis (excluding non-melanoma skin cancer * unable to commit to intervention schedule.
first time in man study of finafloxacin hydrochloride

Conditions: Helicobacter Infections; Urinary Tract Infection

Summary: the purpose of this study is to study the safety of single doses and multiple doses of finafloxacin hydrochloride in healthy volunteers. the level of finafloxacin hydrochloride will be measured in the subjects blood and urine. one part of the study will assess if finafloxacin hydrochloride eradicates helicobacter pylori, a stomach bacteria. another part of the study will assess the activity of the drug in urine.

new antibiotics are needed due to the increasing resistance of bacteria to existing antibiotics. helicobacter pylori (h. pylori) is a bacteria of the stomach and has been shown to cause peptic ulcers and is implicated in gastric cancer. up to 40% of the population has h. pylori. current treatments used to eradicate h. pylori are a combination of a number of drugs including antibiotics and drugs which reduce the acid in the stomach. these treatments are complicated and some h. pylori is resistant to the antibiotics used. this study is the first use of finafloxacin hydrochloride in man and will examine its safety and make a preliminary study of its effectiveness as a single agent in eradicating h. pylori. the urine of subjects will also be used to test its effectiveness in killing the bacteria which cause urinary tract infections.

Eligibility criteria:
inclusion criteria: * male or female healthy subjects * 18-55 years of age * in good health * for part c only, helicobacter pylori carrier status as assessed by a positive result of the urease breath test at screening. exclusion criteria: * abnormal physical findings of clinical significance at the screening examination or baseline which would interfere with the objectives of the study.

Keywords: helicobacter pylori fluoroquinolones first in man
boosting recanalization of thrombectomy for ischemic stroke by intra-arterial tnk (bretis-tnk)

Conditions: Ischemic Stroke

Summary: thrombolysis and endovascular thrombectomy are the most efficient treatments for acute ischemic stroke patients in time window. however, sufficient recanalization (mtici2b-3) can 't be acquired in all patients under thrombectomy. the extend-ia tnk study indicated that tenecteplase before thrombectomy was associated with a higher incidence of reperfusion and better functional outcome than alteplase among patients with ischemic stroke treated within 4.5 hours after symptom onset. this study intends to explore whether a combination of thrombectomy and intra-arterial tnk administration can increase recanalization rate after the first attempt of thrombectomy device pass for ischemic stroke.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years; 2. patients who presented with acute ischemic stroke and a large vessel occlusion in the anterior circulation and met the criteria of mechanical thrombectomy; 3. the subtype of ischemic stroke is large-artery atherosclerosis according to toast classification; 4. the availability of informed consent. exclusion criteria: 1. other sub-types of ischemic stroke such as cardioembolism. 2. hemorrhagic stroke such as cerebral hemorrhage, subarachnoid hemorrhage. 3. coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia (\<100000/mm3). 4. severe hepatic or renal dysfunction, increase in alt or ast (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis. 5. severe uncontrolled hypertension (systolic blood pressure over 200mmhg or diastolic blood pressure over 110 mmhg). 6. patients allergic to any ingredient of drugs in our study. 7. unsuitable for this clinical studies assessed by researcher.